Table 1.
Baseline demographics and patient characteristics (N = 68)
| Age, y | |
| Median | 54.0 |
| Range | 26–84 |
| Sex, n (%) | |
| Male | 44 (64.7) |
| Female | 24 (35.3) |
| Race or ethnic background, n (%) | |
| White | 66 (97.1) |
| Black or African American | 2 (2.9) |
| ECOG score, n (%)a (n = 67) | |
| 0 | 21 (31.3) |
| 1 | 43 (64.2) |
| 2 | 3 (4.5) |
| Tumor type, n (%) | |
| Basal cell carcinoma | 33 (48.5) |
| Pancreatic | 8 (11.8) |
| Colorectal | 3 (4.4) |
| Mesothelioma | 3 (4.4) |
| Small cell lung | 3 (4.4) |
| Adenocystic carcinoma | 2 (2.9) |
| Adrenocortical carcinoma | 2 (2.9) |
| Parotid gland | 2 (2.9) |
| Prostate | 2 (2.9) |
| Medulloblastoma | 1 (1.5) |
| Otherb | 9 (13.2) |
| Previous therapies, n (%) | |
| Surgery | 67 (98.5) |
| Radiotherapy | 36 (52.9) |
| Systemic therapyc | 48 (70.6) |
a
ECOG scores ranging from 0 to 5, with higher scores indicating a greater severity of illness.
b
Other tumor types included one each of appendix, bladder, carcinoid, chondrosarcoma, endometrial, gastric, liver/biliary, melanoma, and renal.
c
Includes hormonal, other biologic, chemotherapy, and other systemic therapy.